Goldman Sachs upgraded Biogen (NASDAQ: BIIB) from Neutral to Buy with a price target of $338.00 (from $228.00).Analyst Dr. Terrance ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE